Changes in Serum MicroRNAs after Anti-IL-5 Biological Treatment of Severe Asthma

Autor: Victoria Del Pozo, José M Rodrigo-Muñoz, José A Cañas, Marcela Valverde-Monge, Beatriz Sastre, Joaquín Sastre, Manuel J Rial
Přispěvatelé: UAM. Departamento de Medicina, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD)
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
MAPK/ERK pathway
Male
Severe asthma
lcsh:Chemistry
0302 clinical medicine
Reslizumab
Medicine
Anti-Asthmatic Agents
lcsh:QH301-705.5
Spectroscopy
mepolizumab
General Medicine
Middle Aged
Computer Science Applications
microRNAs
Treatment Outcome
Biomarker (medicine)
Female
Signal transduction
medicine.drug
Adult
severe asthma
Medicina
Antibodies
Monoclonal
Humanized
Catalysis
Article
Inorganic Chemistry
03 medical and health sciences
microRNA
Humans
Physical and Theoretical Chemistry
Molecular Biology
Anti-IL5 biologics
Mepolizumab
Asthma
anti-IL5 biologics
business.industry
Organic Chemistry
biomarkers
medicine.disease
reslizumab
Microvesicles
MicroRNAs
030104 developmental biology
030228 respiratory system
Gene Expression Regulation
lcsh:Biology (General)
lcsh:QD1-999
Immunology
Interleukin-5
business
Biomarkers
Zdroj: International Journal of Molecular Sciences, Vol 22, Iss 3558, p 3558 (2021)
Biblos-e Archivo. Repositorio Institucional de la UAM
instname
International Journal of Molecular Sciences
Volume 22
Issue 7
ISSN: 1661-6596
1422-0067
Popis: There is currently enough evidence to think that miRNAs play a role in several key points in asthma, including diagnosis, severity of the disease, and response to treatment. Cells release different types of lipid double-membrane vesicles into the extracellular microenvironment, including exosomes, which function as very important elements in intercellular communication. They are capable of distributing genetic material, mRNA, mitochondrial DNA, and microRNAs (miRNAs). Serum miRNA screening was performed in order to analyze possible changes in serum miRNAs in 10 patients treated with reslizumab and 6 patients with mepolizumab after 8 weeks of treatment. The expression of miR-338-3p was altered after treatment (p <
0.05), although no significant differences between reslizumab and mepolizumab were found. Bioinformatic analysis showed that miR-338-3p regulates important pathways in asthma, such as the MAPK and TGF-β signaling pathways and the biosynthesis/degradation of glucans (p <
0.05). However, it did not correlate with an improvement in lung function. MiRNA-338-3p could be used as a biomarker of early response to reslizumab and mepolizumab in severe eosinophilic asthmatic patients. In fact, this miRNA could be involved in airway remodeling, targeting genes related to MAPK and TGF-β signaling pathways.
Databáze: OpenAIRE
Externí odkaz: